Zentalis (ZNTL) officer gets 100,000 stock options at $2.84 grant disclosed

Rhea-AI Filing Summary

Zentalis Pharmaceuticals, Inc. reported that officer Vincent Vultaggio received a stock option grant for 100,000 shares on January 8, 2026. The options have an exercise price of $2.84 per share and expire on January 7, 2036. Following this grant, he beneficially owns 100,000 stock options directly.

According to the footnote, the options vest over four years in substantially equal monthly installments, and vesting depends on his continued service with the company. This structure ties the long-term value of the award to his ongoing tenure and the company’s future performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Vultaggio Vincent

Role PAO and PFO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	100,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 100,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vultaggio Vincent

(Last) (First) (Middle)

C/O ZENTALIS PHARMACEUTICALS, INC.

10275 SCIENCE CENTER DRIVE, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zentalis Pharmaceuticals, Inc. [ ZNTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PAO and PFO

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.84	01/08/2026		A		100,000		(1)	01/07/2036	Stock Option	100,000	$0	100,000	D

Explanation of Responses:

1. The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ James B. Bucher, attorney-in-fact for Vincent Vultaggio	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ZNTL report in this Form 4?

The company reported that officer Vincent Vultaggio received a grant of 100,000 stock options on January 8, 2026.

What is the exercise price and term of the new ZNTL stock options?

The stock options have an exercise price of $2.84 per share and expire on January 7, 2036.

How do Vincent Vultaggio’s ZNTL stock options vest?

The options vest over four years in substantially equal monthly installments, subject to his continued service with the company.

How many ZNTL derivative securities does the officer own after this grant?

After the reported transaction, Vincent Vultaggio beneficially owns 100,000 stock options directly.

Is this ZNTL Form 4 transaction a direct or indirect holding?

The filing states the ownership form as Direct (D), indicating the options are held directly by the reporting person.

What role does the reporting person hold at Zentalis Pharmaceuticals (ZNTL)?

Vincent Vultaggio is an officer of Zentalis Pharmaceuticals, Inc., serving as PAO and PFO.